The Canadian operations plant where Mallinckrodt makes the API for its controversial—and pricey—H.P. Acthar Gel is expanding and getting some Canadian tax dollars to help with the expense. More: Mallinckrodt invests 0M in its BioVectra CDMO Source: fierce
read moreActivist investor Starboard Value is ratcheting up its effort to sway BMS shareholders to vote “no” on its $74 billion acquisition of Celgene. BMS has responded with a 46-page investor presentation laying out its reasoning for completing the deal. More:
read moreFor years now, Teva has had difficulty with the laser drilling of a schizophrenia drug so that patients get the right dose. The FDA, having finally tired of the company being unable to resolve the issues, has now slapped the
read moreJohnson & Johnson just won the first approval for a new depression drug in years: Spravato, a tweaked version of the anesthesia medication—and street drug—ketamine. J&J has blockbuster hopes, but the drug comes with risks and restrictions that could hamper
read moreNICE has requested further evidence on Amgen’s Blincyto for the treatment of adults with acute lymphoblastic leukaemia. More: NICE evidence request for Blincyto for acute lymphoblastic leukaemia Source: News
read moreA patient treated with a stem cell transplant has been in remission from HIV for 18 months and is no longer taking HIV drugs. More: Milestone reached as HIV remission achieved in second patient Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals